On May 24-25, Shenzhen-Hong Kong and Macao Science and Technology Collaborative Innovation Cooperation and the fourth annual Shenzhen-Hong Kong and Macao Science and Technology Exchange special event was held in Macao. Shi Yuanyuan, chairman of our company, was invited by Shenzhen Science and Technology Association and Macao University of Science and Technology to attend and make a keynote report. Attending the event were Fan Yingyan, member of the Party Leadership Group of Guangdong Association for Science and Technology and full-time Vice President; Wang Rui, Academician of Chinese Academy of Engineering and Executive Director of Institute of Materia Medica of Chinese Academy of Medical Sciences; Jiang Zhihong, Vice President of Macao University of Science and Technology and Director of State Key Laboratory of Quality Research of Traditional Chinese Medicine; Qiu Dagan, Member of the Legislative Council of Hong Kong; He Peizheng, Honorary President of Macao Brand Innovation Association, Jiang Yuyang, Chairman of Shenzhen Association for Science and Technology, Sun Nan, member of the Party Group, and biomedical experts, scholars and entrepreneurs from Shenzhen, Hong Kong, Hong Kong lawmakers, Macao SAR government officials and representatives of organizations. The event aims to establish a new pattern of multi-level and all-round cooperation in science and technology innovation in the Greater Bay Area, explore a new collaborative mechanism for innovative drug research and development in the Bay Area, and explore the path of international development of biomedicine.

During the theme forum session, Academician Wang Rui, Vice President Jiang Zhihong, Director of China Resources Sanjiu Joint Engineering Center Zhang Yuefei, President of Shenzhen Unknown Jun Biotechnology Co., LTD. Tan Jian, president of Shenzhen Cell Valley Biomedicine Co., LTD. Shi Yuan, president of Donge Ejiao Co., LTD. Cheng Jie and other six guests gave keynote speeches. Topics in the field of biomedicine, such as innovative drug research and development, innovative drug green synthesis technology, and complex preparation technology, were discussed.

The cell therapy industry has great medical value and broad development prospects. As an economic and industrial plateau, the Guangdong-Hong Kong-Macao Greater Bay Area has become an important task in recent years to build a whole-chain service platform for new drug research and development and achievement transformation in the Greater Bay Area, and to accelerate the construction of the innovative drug center of the "Science and Innovation China" Greater Bay Area consortium.

At the forum, Professor Shi Yuanyuan, chairman of the board, gave a speech on the status quo and prospect of cell therapy, mainly introducing the background and status quo of cell therapy, the principle and mechanism of CAR-T therapy, the selection of viral vectors, development prospects, and the development process, technical advantages and comprehensive strength of Shenzhen Cell Valley

Shi Yuan said that Shenzhen Cell Valley is currently the only domestic enterprise with an industrialized production line of reverse-virus vector and a CAR T cell factory production line. As a major public service platform for the biomedical industry, it will continue to improve the overall level of pharmaceutical innovation in the Greater Bay Area. To provide services and technical support to domestic enterprises, research institutes and medical institutions in the field of cell and gene therapy, to explore therapeutic means, to carry out cutting-edge research, to promote cell therapy technology from the laboratory to the clinic, to guide relevant enterprises in the Greater Bay Area to innovate and practice in the field of biomedicine, and to deepen industry-university research cooperation. Establish a refined and convenient mechanism for the transfer and transformation of scientific and technological achievements and a mass innovation platform, form a diversified drug research and development model, and fully stimulate the enthusiasm and vitality of innovation and entrepreneurship in the biomedical industry; At the same time, we will jointly establish a sound review and uation mechanism with various review institutions, standardize the macro and micro policies of the cell industry, strengthen the supervision and management of cell clinical trials and applications, explore effective governance systems, and promote the rapid transformation of innovative results and market promotion. And continue to transport the shortage of high-end technical talents for the industrial production of cell therapy, and provide strong support for promoting the emerging biotechnology industry.

Shenzhen Cell Valley will give full play to its own advantages, strengthen cooperation with the Greater Bay Area, promote cross-regional exchanges of talent flow and technological innovation, build an influential biomedical industry cluster, and make important contributions to the economic development of the Greater Bay Area.

(Photo provided by the organizer, some text materials from Shenzhen News Network)